title: Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b.
abstract: OBJECTIVE
  Interferon-alpha treatment is associated with a large number of adverse effects. Depressive symptoms are not unexpected, and potentially dangerous psychiatric adverse effects can induce life-threatening conditions. We compared the incidence of depressive symptoms in patients with chronic hepatitis C during treatment with pegylated interferon-alpha-2a (IFNalpha-2a) and pegylated interferon-alpha-2b (IFNalpha-2b).
  
  
  METHODS
  We randomly divided 186 subjects with chronic hepatitis C into two treatment groups: group A, treated with IFNalpha-2a, and group B, treated with IFNalpha-2b. Treatment was continued for up to 48 weeks. Liver biopsy and hepatitis C virus RNA assay were carried out in all patients. Depressive symptoms and the prevalence of psychiatric adverse effects during treatment with IFN were evaluated using the Hamilton Depression Rating Scale, the Zung Self-Rating Depression Scale, and the Structured Clinical Interview for Diagnostic and Statistic Manual-IV axis disorders.
  
  
  RESULTS
  At baseline 53% of subjects in group A and 57% of subjects in group B presented with depressive symptoms; at 12 weeks we found a high incidence of depressive symptoms in both groups (group A 61% and group B 65%) and three cases of life-threatening psychiatric symptoms (i.e. psychosis and delirium requiring discontinuation of antiviral therapy and admission to a psychiatric unit) in group A.
  
  
  CONCLUSIONS
  Long-term administration of IFN can be associated with serious psychiatric adverse effects. It is very important that psychiatric symptoms are diagnosed early in IFN treatment so to improve treatment compliance and prevent fatal and/or life-threatening adverse events, as were documented in some subjects treated with IFNalpha-2a in our study.
authors.affiliation: Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy. sergio.ner4@tin.it
authors.forename: Sergio
authors.initials: S
authors.lastname: Neri
authors.forename: Davide
authors.initials: D
authors.lastname: Pulvirenti
authors.forename: Gaetano
authors.initials: G
authors.lastname: Bertino
mesh_terms: D000328:Adult; D000998:Antiviral Agents / Q000009:adverse effects*; D003863:Depression / Q000139:chemically induced; D005260:Female; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000523:psychology; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects*; D008297:Male; D008875:Middle Aged; D010349:Patient Compliance; D011092:Polyethylene Glycols / Q000009:adverse effects*; D011446:Prospective Studies; D011605:Psychoses, Substance-Induced / Q000209:etiology*; D011994:Recombinant Proteins
chemical_list: D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; C417083:peginterferon alfa-2b; C100416:peginterferon alfa-2a